TABLE 1

Characteristics of 9vHPV Reports to VAERS, 2014–2017

Report CharacteristicsFemaleMaleUnknown SexTotal Reports
Total reports, n2258156634207244
 Serious reportsa,b116 (5.1)65 (4.1)5 (0.1)186 (2.6)
 9vHPV given alone1393 (61.7)736 (47)3282 (95.7)5411 (74.7)
Type of reporter, n (%)
 Manufacturer825 (36.5)432 (27.6)3393 (99.2)4650 (64.2)
 Health care provider1071 (47.4)863 (55.1)8 (0.2)1942 (26.8)
 Patient or parent162 (7.2)92 (5.9)0254 (3.5)
 Other200 (8.9)179 (11.4)19 (0.6)398 (5.5)
Age groups, y, n (%)
 <9c22 (0.9)17 (1.1)45 (1.3)84 (1.2)
 9–171434 (63.5)1165 (74.4)393 (11.5)2992 (41.3)
 18–26398 (17.6)185 (11.8)48 (1.4)631 (8.7)
 >26c35 (1.5)13 (0.8)9 (0.3)57 (0.8)
 Not reported or unknown369 (16.3)186 (11.9)2925 (85.5)3480 (48)
Median onset from time of vaccination to AE symptoms (range), dd0 (0–527)0 (0–610)0 (0–751)0 (0–751)
  • a Includes hospitalization, prolongation of existing hospitalization, permanent disability, life-threatening illness, congenital anomaly or birth defect, or death as defined in 21CFR600.80.21

  • b Includes 4 reports of death in females, 2 reports of death in males, and 1 report of death in an individual of unknown sex.

  • c 9vHPV is not approved for children <9 y and was not approved for adults >26 y during the analytic period.

  • d Day 0 is the day of vaccination.